In April 2022, HOPA submitted a proposal to the Board of Pharmacy Specialties to continue to provide professional development programs for the recertification of board-certified pharmacists. With BPS's approval, HOPA is proud to provide Board Certified Oncology Pharmacy (BCOP) continuing education for another seven years. The new contract begins January 1, 2024 and runs through December 31, 2030.

Read the announcement: BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024


HOPA Provides at Least 60 BCOP CEs Each Year

Each year, HOPA provides at least 60 BCOP Continuing Education Credits for members and other board certified hematology/oncology pharmacists. Explore the latest BCOP Updates and BCOP Self-Study Releases and more!

X-ray of brain with desmoid tumors
Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Nirogacestat (Ogsiveo)

Brooke Lochridge, PharmD ,PGY-2 Oncology Pharmacy Resident, of Tristar Centennial Medical Center, Nashville, TN, and Colleen McCabe, PharmD, BCOP, Oncology Clinical Specialist, Sarcoma & Melanoma from Vanderbilt University Medical Center, Nashville, TN w

high-risk neuroblastoma
Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Eflornithine for High-Risk Neuroblastoma

Taylor Gullickson, PharmD, PGY1 Pharmacy Resident and Alexis Kuhn, PharmD, BCOP, Pediatric Oncology Pharmacist, from Mayo Clinic Rochester, Minnesota write about Eflornithine for High-Risk Neuroblastoma.

close up photo of colon cancer cells
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Fruquintinib

Hunter Sowell, PharmD, PGY-2 Oncology Pharmacy Resident and Sarah Cimino, PharmD, BCOP, Clinical Pharmacist Specialist, Gastrointestinal Oncology, both from Vanderbilt University Medical Center, write about fruquintinib.